Funded Biotechnology Startups in Israel
The 50 most recent funding rounds in Israeli biotechnology span September 2022 through November 2025 across therapeutics, medical devices, alternative prot…
The 50 most recent funding rounds in Israeli biotechnology span September 2022 through November 2025 across therapeutics, medical devices, alternative proteins, and agri-biotech. The largest disclosed amounts stand well above the field: InSightec (Tirat Carmel) raised $150M in June 2024, InspireMD (Tel Aviv) closed $114M in May 2023, and MitrAssist (Misgav Dov) secured $100M in September 2023. CytoReason's $80M Series B in July 2024 is the largest named-stage round in the set.
Nineteen of the 50 companies are headquartered in the Tel Aviv district — including Herzliya, Or Yehuda, and Ramat Hasharon — making it the dominant geography. Ness Ziona in the Hamerkaz region is the most concentrated single city outside that metro, with seven companies including IBI-Ag, BIOMx, Kadimastem, and Enlivex Therapeutics. Round-stage disclosure is sparse: most entries carry "Series Unknown" classification, though the set also includes five Series A deals, three Series B, two Series C, one Series D, four Seed rounds, one Angel, and one Grant.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this Israeli biotech dataset?
InSightec (Tirat Carmel) raised $150M in June 2024, followed by InspireMD (Tel Aviv) at $114M in May 2023 and MitrAssist (Misgav Dov) at $100M in September 2023. CytoReason's $80M Series B in July 2024 is the top deal with an explicitly named stage, and Omnix Medical's $25M Series C in October 2025 is the largest named-stage round from 2025.
Which cities have the highest concentration of funded Israeli biotech companies in this list?
The Tel Aviv district — the city itself plus suburbs including Herzliya, Or Yehuda, Tel Aviv-yafo, and Ramat Hasharon — accounts for 19 of the 50 companies shown. Ness Ziona in the Hamerkaz region is the most-represented single city outside that metro, with seven companies: IBI-Ag, BIOMx, Kadimastem, Enlivex Therapeutics, DOT Compliance, WeedOut, and MeaTech. Jerusalem accounts for four companies including Omnix Medical and KAHR Medical.
How recent is the funding activity shown here?
Thirteen of the 50 rounds date from 2025, the most recent being IBI-Ag's $4M Series A on November 16, 2025, and Renewal Bio's undisclosed venture round on November 11, 2025. The 2025 cohort includes both larger raises — Omnix Medical's $25M Series C in October — and micro-financings such as Kadimastem's $170K in July and NurExone Biologic's $560K in August.
What sub-sectors appear across these Israeli biotech companies?
The 50 entries span drug development (Lutris Pharma, CanFite BioPharma, Neurolief), medical devices (Omnix Medical, EndoSpan, Vessi Medical, MitrAssist), alternative proteins (Brevel, Ever After Foods, MeaTech, Newmoo), cell therapy (Minovia, Kadimastem, Enlivex Therapeutics), microbiome and phage therapy (BIOMx, Biomica, Pangea Biomed), and agri-biotech (IBI-Ag, Phytolon, WeedOut).
What funding stages are represented and how well-disclosed are the rounds?
Most rounds carry a "Series Unknown" label, consistent with publicly listed Israeli biotech companies raising through secondary offerings or less-disclosed mechanisms. Named stages present include five Series A deals (IBI-Ag, Gavan, WeedOut, Vessi Medical, Append Medical), three Series B (Restore Medical, CytoReason, DOT Compliance), two Series C (Omnix Medical, MitrAssist), one Series D (RedDress), four Seed rounds, one Angel (NeuroBrave), and one Grant (Azura Ophthalmics).
Do the round sizes in this dataset vary significantly?
The range is wide. Kadimastem raised $170K in July 2025, BOB FoodTech $320K in October 2024, and NurExone Biologic $560K in August 2025 — micro-raises typical of publicly listed firms doing incremental equity offerings. Those sit in the same 50-entry window as InSightec's $150M and MitrAssist's $100M, indicating the dataset reflects both growth-stage medtech and micro-cap bridge activity simultaneously.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.